Preclinical and clinical evaluation through serial colonoscopic evaluation of neratinib‐induced diarrhea in HER2 ‐positive breast cancer—A pilot study
Physiological Reports · 2024
DOI: 10.14814/phy2.70008 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Physiological Reports, 2024. Verfasst von Joanne Bowen und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Biomedicine, The University of Adelaide, Adelaide, South Australia, Australia. Hauptthemen laut MEDLINE: Diarrhea, Breast Neoplasms, Quinolines, Rats, Wistar. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Puma Biotechnology (Puma Biotechnology, Inc.).
Abstract (Originalsprache)
The irreversible pan‐HER tyrosine kinase inhibitor neratinib is approved for patients with HER2‐positive, early‐stage and metastatic breast cancer (BC). Neratinib‐associated diarrhea is the most common reason for early discontinuation. Preclinical studies identified mechanisms of neratinib‐induced diarrhea and rationale for prophylactic and preventive measures. We studied effects of neratinib on rat intestines and conducted a phase 2 study of colon pathogenesis in patients with HER2‐positive BC treated with neratinib (NCT04366713). Colon samples from female albino Wistar rats receiving neratinib or vehicle were examined for histopathological changes. Patients with HER2‐positive BC received neratinib 240 mg once daily for up to 1 year. Colonoscopy biopsies were collected at baseline and at Day 28 to identify changes consistent with rat pathologies. Rat colons were markedly altered in appearance, with similar short circuit currents ( I sc ) and responses to carbachol and forskolin. Mucosal barrier loss and/or significant increase in secretory propensity in neratinib‐ versus control‐treated animals were not seen. Two of four endpoint‐evaluable patients presented with mild pathological changes, largely comparable with the rat model. Preclinical evidence supports an inflammatory component of neratinib‐induced diarrhea without mucosal barrier function loss. Colonoscopy findings in patients with BC indicate mild or no pathological changes in the colon due to neratinib treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Biomedicine, The University of Adelaide, Adelaide, South Australia, Australia.
- Medical Oncology, Hospital Prof. Doutor Fernando Fonseca, EPE, Amadora, Portugal.
- Department of Pathology, The University of Alabama at Birmingham, Birmingham, Alabama, USA.
- Division of Research and Innovation, University of Adelaide, Adelaide, South Australia, Australia.
- Puma Biotechnology, Inc., Los Angeles, California, USA.
- Division of Gastroenterology, University of South Alabama, College of Medicine, Mobile, Alabama, USA.
ORCID-Profile: Joanne Bowen
Förderung
- Puma Biotechnology (Puma Biotechnology, Inc.)
Zitieren
APA
Bowen, J., Braga, S., Zotto, V. D., Finnie, J., DiPrimeo, D., Cooke, B., Bischof, G. F., Wong, A., & Di Palma, J. A. (2024). Preclinical and clinical evaluation through serial colonoscopic evaluation of neratinib‐induced diarrhea in HER2 ‐positive breast cancer—A pilot study. Physiological Reports. https://doi.org/10.14814/phy2.70008
Vancouver
Bowen J, Braga S, Zotto VD, Finnie J, DiPrimeo D, Cooke B, et al. Preclinical and clinical evaluation through serial colonoscopic evaluation of neratinib‐induced diarrhea in HER2 ‐positive breast cancer—A pilot study. Physiological Reports. 2024. doi:10.14814/phy2.70008
BibTeX
@article{Bowen2024,
author = {Bowen, Joanne and Braga, Sofia and Zotto, Valeria Dal and Finnie, John and DiPrimeo, Daniel and Cooke, Blaire and Bischof, Georg F and Wong, Alvin and Di Palma, Jack A},
title = {Preclinical and clinical evaluation through serial colonoscopic evaluation of neratinib‐induced diarrhea in HER2 ‐positive breast cancer—A pilot study},
journal = {Physiological Reports},
year = {2024},
doi = {10.14814/phy2.70008}
}
EUVIMED